Investor Stock List
Ranked #3,446 of 8,699 institutional investors

Sanofi

Paris, I0

$550M
US stock portfolio at live prices · today +$7.1M (+1.30%)
Market closed. Prices as of Nov 20, 6:11 AM ET
Value at quarter end (Q3 2026)
$630M
Change from Q2 2026
+$95.8M (+17.94%)
Positions
15 · 6 new, 0 sold out
Filed
Nov 5, 2026

Not counted in the ranking: none$134M of holdings we could not match to a US listing are included at their reported quarter-end value.

Holdings

Q3 2026 13F, live prices
INBX 15.7%KRSA 12.9%NVAX 9.66%ANAB 7.09%TRAX 6.65%
StockSharesValue, live% of portfoliovs Q2 2026
INBX Inhibrx Biosciences, Inc.1,157,926$86.1M15.7%Unchanged
KRSA Korsana Biosciences, Inc.1,994,011$70.7M12.9%New
NVAX Novavax, Inc.6,880,481$53.1M9.66%Unchanged
ANAB AnaptysBio, Inc.821,917$39.0M7.09%Unchanged
TRAX First Tracks Biotherapeutics, Inc.821,917$36.5M6.65%Unchanged
ODTX Odyssey Therapeutics, Inc.1,990,200$36.5M6.64%Unchanged
ETRA Electra Therapeutics, Inc.2,461,948$22.0M4.00%New
ATTO Attovia Therapeutics, Inc.1,082,855$16.9M3.07%New
AGMB AgomAb Therapeutics NV2,783,096$15.6M2.85%Unchanged
IMRX Immuneering Corporation2,708,559$9.3M1.70%Unchanged
LTGO Latigo Biotherapeutics, Inc.672,778$8.9M1.62%New
SCTX Scribe Therapeutics Inc.500,000$6.6M1.20%New
SABS SAB Biotherapeutics, Inc.2,198,500$6.4M1.16%New
MPLT MapLight Therapeutics, Inc.912,041$5.9M1.07%Unchanged
QTTB Q32 Bio Inc.244,083$2.1M0.38%Unchanged